A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors (NCT07182149)
A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination With Immune Checkpoint Inhibition in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.
Who can join: Review the eligibility criteria below.
Location: Normunity Investigational Site — Denver, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- Normunity Investigational Site — Denver, Colorado
- Normunity Investigational Site — New Haven, Connecticut
- Normunity Investigational Site — Washington D.C., District of Columbia
- Normunity Investigational Site — Boston, Massachusetts
- Normunity Investigational Site — Boston, Massachusetts
- Normunity Investigational Site — Minneapolis, Minnesota
- Normunity Investigational Site — St Louis, Missouri
- Normunity Investigational Site — Hackensack, New Jersey
- Normunity Investigational Site — Maumee, Ohio
- Normunity Investigational Site — Oklahoma City, Oklahoma
- Normunity Investigational Site — Philadelphia, Pennsylvania
- Normunity Investigational Site — Philadelphia, Pennsylvania
- Normunity Investigational Site — Charleston, South Carolina
- Normunity Investigational Site — Nashville, Tennessee
- Normunity Investigational Site — Dallas, Texas
- Normunity Investigational Site — Houston, Texas
- Normunity Investigational Site — San Antonio, Texas
- Normunity Investigational Site — Fairfax, Virginia
📞 Contact the Study Coordinator
Phone: (215) 593-7119
Email: judy.schnyder@normunity.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HNSCC
- Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors — Portland, Oregon
- Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC — Cincinnati, Ohio
- Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) — Nashville, Tennessee
- Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC — Orange, California
- Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer — Nashville, Tennessee
Explore by condition: All HNSCC clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.